The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine

被引：0
|
作者：
Papageorgiou, Sotirios
Kontos, Christos K.
Tsiambalis, Thomas
Vyniou, Athina
Symeonidis, Argiris
Galanopoulos, Athanasios
Kotsianidis, Ioannis
Pappa, Vassiliki
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4252
引用
收藏
页数：3
相关论文
共 50 条
  • [31] EXPERIENCE WITH THE USE OF 5-AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OF LOW/INTERMEDIATE RISK
    Llorente Dunia, De Miguel
    Lopez Nuria, Golbano
    Morfa Miguel, Diaz
    Juanis Jaime, Arbeteta
    Sanz Dolores, Morales
    Perez Dolores, Subira
    Maqueda Cristina, Fernandez
    Ramo Alejandro, Vazquez
    Martin Sonia, Herrero
    Albiz Blanca, Pinedo
    HAEMATOLOGICA, 2016, 101 : 152 - 152
  • [32] Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine
    Isabel Möller
    Sabine Blum
    Norbert Gattermann
    Rainer Haas
    Kerstin Habersang
    Ulrich Germing
    Andrea Kuendgen
    Annals of Hematology, 2009, 88 : 1141 - 1144
  • [33] SINGLE INSTITUTION EXPERIENCE OF 5-AZACITIDINE THERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
    Freyrie, A.
    Guidotti, F.
    Reda, G.
    Binda, F.
    Cortelezzi, A.
    HAEMATOLOGICA, 2012, 97 : 587 - 587
  • [34] Clinical significance of CD41-positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine
    Ogata, Kiyoyuki
    Sei, Kazuma
    Kawahara, Naoya
    Yamamoto, Yumi
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : E142 - E145
  • [35] RESPONSE TO 5-AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND SECUNDARY AML: RESULTS FROM UNIQUE HOSPITAL
    De Miguel, M. D.
    Golbano, N.
    San Roman, M. I. Lopez
    Morfa, M. Diaz
    Arbeteta, J.
    Morales, D.
    Pinedo, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 567 - 567
  • [36] Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine
    Moeller, Isabel
    Blum, Sabine
    Gattermann, Norbert
    Haas, Rainer
    Habersang, Kerstin
    Germing, Ulrich
    Kuendgen, Andrea
    ANNALS OF HEMATOLOGY, 2009, 88 (11) : 1141 - 1144
  • [37] Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
    Santini, V.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    List, A. F.
    Silverman, L. R.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] GLOBAL DNA METHYLATION PREDICTS THE RESPONSIVENESS TO AZACITIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Poloni, A.
    Goteri, G.
    Zizzi, A.
    Serrani, F.
    Costantini, B.
    Trappolini, S.
    Mariani, M.
    Leoni, P.
    HAEMATOLOGICA, 2012, 97 : 133 - 133
  • [39] Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes
    Fenaux, Pierre
    Ades, Lionel
    LEUKEMIA RESEARCH, 2009, 33 : S7 - S11
  • [40] Treatment of patients with high-risk myelodysplastic syndromes
    Gattermann, Norbert
    Kuendgen, Andrea
    Germing, Ulrich
    CANCER TREATMENT REVIEWS, 2007, 33 : S64 - S68
12345